1921
Volume 101, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The WHO recommends mass treatment with praziquantel as the primary approach for –related morbidity control in endemic populations. The Schistosomiasis Consortium for Operational Research and Evaluation implemented multi-country, cluster-randomized trials to compare effectiveness of community-wide and school-based treatment (SBT) regimens on prevalence and intensity of schistosomiasis. To assess the impact of two different treatment schedules on –associated morbidity in children, cohort studies were nested within the randomized trials conducted in villages in Kenya and Tanzania having baseline prevalence ≥ 25%. Children aged 7–8 years were enrolled at baseline and followed to ages 11–12 years. Infection intensity and odds of infection were reduced both in villages receiving four years of annual community-wide treatment (CWT) and those who received biennial SBT over 4 years. These regimens were also associated with reduced odds of undernutrition and reduced odds of portal vein dilation at follow-up. However, neither hemoglobin levels nor the prevalence of the rare abnormal pattern C liver scores on ultrasound improved. For the combined cohorts, growth stunting worsened in the areas receiving biennial SBT, and maximal oxygen uptake as estimated by fitness testing scores declined under both regimens. After adjusting for imbalance in starting prevalence between study arms, children in villages receiving annual CWT had significantly greater decreases in infection prevalence and intensity than those villages receiving biennial SBT. Although health-related quality-of-life scores improved in both study arms, children in the CWT villages gained significantly more. We conclude that programs using annual CWT are likely to achieve better overall morbidity control than those implementing only biennial SBT.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0273
2019-08-12
2020-10-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/6/tpmd190273.html?itemId=/content/journals/10.4269/ajtmh.19-0273&mimeType=html&fmt=ahah

References

  1. Colley DG, Bustinduy AL, Secor WE, King CH, 2014. Human schistosomiasis. Lancet 383: 22532264.
    [Google Scholar]
  2. Bustinduy AL, King CH, 2014. Schistosomiasis. Farrar J, Hotez PJ, Junghanns T, Kang G, Lalloo DG, White NJ, eds. Manson’s Tropical Diseases, 23rd edition. Philadelphia, PA: Elsevier Saunders, 698725.
    [Google Scholar]
  3. Ezeamama AE, Bustinduy AL, Nkwata AK, Martinez L, Pabalan N, Boivin MJ, King CH, 2018. Cognitive deficits and educational loss in children with schistosome infection-a systematic review and meta-analysis. PLoS Negl Trop Dis 12: e0005524.
    [Google Scholar]
  4. World Health Organization, 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: Report of a WHO Expert Committee. Technical Report Series 912. Geneva, Switzerland: WHO, 157.
    [Google Scholar]
  5. World Health Organization, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: WHO.
    [Google Scholar]
  6. World Health Organization, 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Geneva, Switzerland: WHO, 81.
    [Google Scholar]
  7. Ezeamama AE et al., 2016. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. BMC Infect Dis 16: 229.
    [Google Scholar]
  8. Wiegand RE et al., 2017. A persistent hotspot of Schistosoma mansoni infection in a five-year randomized trial of praziquantel preventative chemotherapy strategies. J Infect Dis 216: 14251433.
    [Google Scholar]
  9. Olsen A, Kinung’hi S, Magnussen P, 2018. Comparison of the impact of different mass drug administration strategies on infection with Schistosoma mansoni in Mwanza region, Tanzania-a cluster-randomized controlled trial. Am J Trop Med Hyg 99: 15731579.
    [Google Scholar]
  10. Shen Y et al., 2017. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries. BMC Infect Dis 17: 652.
    [Google Scholar]
  11. Sircar AD, Mwinzi PNM, Onkanga IO, Wiegand RE, Montgomery SP, Secor WE, 2018. Schistosoma mansoni mass drug administration regimens and their effect on morbidity among schoolchildren over a 5-year period-Kenya, 2010–2015. Am J Trop Med Hyg 99: 362369.
    [Google Scholar]
  12. Kinung’hi S, Magnussen P, Kaatano G, Olsen A, 2016. Infection with Schistosoma mansoni has an effect on quality of life, but not on physical fitness in schoolchildren in Mwanza Region, north-western Tanzania: a cross-sectional study. PLoS Negl Trop Dis 10: e0005257.
    [Google Scholar]
  13. Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DM, Wiegand RE, Secor WE, Montgomery SP, 2016. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol 46: 439445.
    [Google Scholar]
  14. Samuels AM, Matey E, Mwinzi PN, Wiegand RE, Muchiri G, Ireri E, Hyde M, Montgomery SP, Karanja DM, Secor WE, 2012. Schistosoma mansoni morbidity among school-aged children: a SCORE project in Kenya. Am J Trop Med Hyg 87: 874882.
    [Google Scholar]
  15. Katz N, Chaves A, Pellegrino J, 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 14: 397400.
    [Google Scholar]
  16. World Health Organization, 2011. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. WHO/NMH/NHD/MNM/11.1. Geneva, Switzerland: WHO.
    [Google Scholar]
  17. Sullivan KM, Mei Z, Grummer-Strawn L, Parvanta I, 2008. Haemoglobin adjustments to define anaemia. Trop Med Int Health 13: 12671271.
    [Google Scholar]
  18. World Health Organization, 2006. Assessment of differences in linear growth among populations in the WHO multicentre growth reference study. Acta Paediatrica Suppl 450: 5665.
    [Google Scholar]
  19. Bustinduy AL, Thomas CL, Fiutem JJ, Parraga IM, Mungai PL, Muchiri EM, Mutuku F, Kitron U, King CH, 2011. Measuring fitness of Kenyan children with polyparasitic infections using the 20-meter shuttle run test as a morbidity metric. PLoS Negl Trop Dis 5: e1213.
    [Google Scholar]
  20. Leger L, Lambert J, Goulet A, Rowan C, Dinelle Y, 1984. Capacité aérobie des Québécois de 6 à 17 ans–test navette de 20 mètres avec paliers de 1 minute. Can J Appl Spt Sci 9: 6469.
    [Google Scholar]
  21. Leger LA, Mercier D, Gadoury C, Lambert J, 1988. The multistage 20 metre shuttle run test for aerobic fitness. J Sports Sci 6: 93101.
    [Google Scholar]
  22. Leger LA, Lambert J, 1982. A maximal multistage 20-m shuttle run test to predict VO2 max. Eur J Appl Physiol Occup Physiol 49: 112.
    [Google Scholar]
  23. Muller I et al., 2011. Effect of schistosomiasis and soil-transmitted helminth infections on physical fitness of school children in Cote d’Ivoire. PLoS Negl Trop Dis 5: e1239.
    [Google Scholar]
  24. Varni JW, Burwinkle TM, Seid M, 2006. The PedsQL 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res 15: 203215.
    [Google Scholar]
  25. Varni JW, Seid M, Rode CA, 1999. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37: 126139.
    [Google Scholar]
  26. Terer CC, Bustinduy AL, Magtanong RV, Muhoho N, Mungai PL, Muchiri EM, Kitron U, King CH, Mutuku FM, 2013. Evaluation of the health-related quality of life of children in Schistosoma haematobium-endemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 7: e2106.
    [Google Scholar]
  27. Magai DN, Koot HM, 2019. Quality of life in children and adolescents in central Kenya: associations with emotional and behavioral problems. Qual Life Res 28: 12711279.
    [Google Scholar]
  28. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM, 2000. Ultrasound in Schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of Schistosomiasis-Related Morbidity. Geneva, Switzerland: WHO.
    [Google Scholar]
  29. Vennervald BJ et al., 2004. Detailed clinical and ultrasound examination of children and adolescents in a Schistosoma mansoni endemic area in Kenya: hepatosplenic disease in the absence of portal fibrosis. Trop Med Int Health 9: 461470.
    [Google Scholar]
  30. Rubin DB, 2004. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons.
    [Google Scholar]
  31. Mohamed I, Kinung’hi S, Mwinzi PNM, Onkanga IO, Andiego K, Muchiri G, Odiere MR, Vennervald BJ, Olsen A, 2018. Diet and hygiene practices influence morbidity in schoolchildren living in schistosomiasis endemic areas along Lake Victoria in Kenya and Tanzania-a cross-sectional study. PLoS Negl Trop Dis 12: e0006373.
    [Google Scholar]
  32. LaBeaud AD et al., 2015. Parasitism in children aged three years and under: relationship between infection and growth in rural coastal Kenya. PLoS Negl Trop Dis 9: e0003721.
    [Google Scholar]
  33. Nayakwadi Singer M et al., 2017. Pneumococcal vaccine response after exposure to parasites in utero, in infancy, or mid-childhood. Pediatrics 139: e20162781.
    [Google Scholar]
  34. Righetti AA, Adiossan LG, Ouattara M, Glinz D, Hurrell RF, N’Goran EK, Wegmuller R, Utzinger J, 2013. Dynamics of anemia in relation to parasitic infections, micronutrient status, and increasing age in south-central Cote d’Ivoire. J Infect Dis 207: 16041615.
    [Google Scholar]
  35. Kittur N, Binder S, Campbell CH, King CH, Kinung’hi S, Olsen A, Magnussen P, Colley DG, 2017. Defining persistent hotspots: areas that fail to decrease meaningfully in prevalence after multiple years of mass drug administration with praziquantel for control of schistosomiasis. Am J Trop Med Hyg 97: 18101817.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0273
Loading
/content/journals/10.4269/ajtmh.19-0273
Loading

Data & Media loading...

Supplemental table

  • Received : 10 Apr 2019
  • Accepted : 26 Jun 2019
  • Published online : 12 Aug 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error